Is the price fair?
What LGND's price assumes
Ligand Pharmaceuticals Incorporated trades at 30.6× earnings against 32.4× for the median Biotechnology name, cheaper than its own group.
30.6
Trailing P/E · Biotechnology median 32.4 · cheaper than the typical name in its group
- Price / sales
- 14.5
Price / sales · as of 2026-Q1
- Free cash flow yield
- 2.4%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +15%
Growth the price implies · The price pays for +15% free cash flow growth a year for a decade; the business has delivered +10% a year over the last three.
Details›
- Price / book2026-Q1
- 3.98
- Healthcare median P/E362 names
- 31.5
- Biotechnology median P/E158 names
- 32.4
- Free cash flow, trailing twelve months
- $131M
- Market capitalisation
- $5.51B
- 3-year revenue growth
- +17%
- 3-year free cash flow growth
- +10%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $200.52 |
| Its own P/E history, median | $276.80 |
| Its own P/E history, upper quartile | $320.36 |
| 52-week range | $147.01 – $316.44 |
| Today | $287.86 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.